The habilitation of 34 thalidomide children, begun in 1963 at the Rehabilitation Institute of Montreal, involved the contribution of many medical and paramedical disciplines. These individual contributions are described.Habilitation of congenitally deformed children must be initiated at an early age. The early prescription of a prosthesis is desirable. Their care involves a broad range of services that must be continued over many years. Parents require support before they can accept the misfortune that has befallen them and their deformed child. Despite the necessity of frequent hospitalizations, children should be reared in a home setting. From their experience, the authors conclude that children born with malformations, and their parents, should be thoroughly evaluated and followed up for many years; and recommend that governments should finance programs for the complete habilitation of all children born with congenital malformations. National registries for the compulsory recording of birth deformities should also be established.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936781 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic orphans, off-label, pediatric drug development: towards reasonable pharmacotherapy for minors.
Expert Opin Pharmacother
December 2024
Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Giannina Gaslini Institute, University of Genova, Genova, Italy.
Introduction: The concept that children are therapeutic orphans emerged in the 1960s, triggering eventually worldwide legislation to facilitate pediatric studies, called 'Pediatric Drug Development (PDD).' However, PDD's true aim is not better medicines for children but labels in minors; minors are not another species.
Areas Covered: Absorption, distribution, metabolism, and excretion (ADME) differ in preterm newborns, but babies mature.
Article Synopsis
- Individuals with thalidomide embryopathy, now around 60 years old, have been coping with physical challenges due to limb development issues and experience secondary problems like pain.
- Previous studies on their skeletal issues through imaging have mainly focused on younger individuals, with limited research on older adults.
- This study used advanced imaging techniques to analyze the skeletons of five older individuals with thalidomide embryopathy, revealing issues such as joint dislocation, osteoarthritis, and abnormal bone development that likely contribute to their upper limb pain.
Machine learning-based identification of biomarkers and drugs in immunologically cold and hot pancreatic adenocarcinomas.
J Transl Med
August 2024
Department of Immunology, School of Medicine, Nantong University, Nantong, 226001, China.
Background: Pancreatic adenocarcinomas (PAADs) often exhibit a "cold" or immunosuppressive tumor milieu, which is associated with resistance to immune checkpoint blockade therapy; however, the underlying mechanisms are incompletely understood. Here, we aimed to improve our understanding of the molecular mechanisms occurring in the tumor microenvironment and to identify biomarkers, therapeutic targets, and potential drugs to improve PAAD treatment.
Methods: Patients were categorized according to immunologically hot or cold PAAD subtypes with distinct disease outcomes.
Effect of CAPEOX combined with thalidomide in the treatment of elderly patients with colon cancer: A single-center report.
Asian J Surg
August 2024
Department of Rehabilitation, University of South China Affiliated Chenzhou Hospital (Chenzhou First People's Hospital), Chenzhou, Hunan, 423000, China. Electronic address:
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Expert Rev Hematol
May 2024
Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Background: To evaluate the efficacy and safety of pomalidomide in combination treatment of relapsed/refractory multiple myeloma (RRMM).
Methods: Published clinical trials were searched in the Cochrane Library, PubMed, EMBASE to February 2023. The literature was screened and evaluated according to the inclusion criteria, and the data were analyzed by a random effect model.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!